Table 3.

Summary of the efficacy data in the SHIV-RT macaque model testing prototype and modified gels^a

Gel	Version	No. of applications	Gel dosing relative to challenge (h)	Protection vs CG gel (%)		No. of infected macaques/no. of challenged macaques		P value vs CG gel
ZA/CGb	Prototype	14 daily	8	78	70	1/7	4/21	0.0089
ZA/CGb	Prototype	14 daily	24	53		2/7
ZA/CGb	Prototype	14 EOD	24	78		1/7
CGb	Prototype	14 daily	8–24	N/A		9/14		N/A
ZA/CG	Modified	14 daily	24	53		2/7		0.1354
CG	Modified	14 daily	8–24	N/A		3/5		N/A
ZA/CG	Poolc	14 daily	24	66		6/28		0.006
CG	Poold	14 daily	8–24	N/A		12/19		N/A

^aEOD, every other day; N/A, not applicable.

^bPublished data (6).

^cPool of the results obtained with the prototype and modified ZA/CG gel (application adaily or EOD for 14 days, with SHIV-RT challenge 8 to 24 h after the last gel application).

^dPool of the results obtained with the prototype and modified CG gel (application daily for 14 days, with SHIV-RT challenge 8to 24 h after the last gel application).